Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Table 5 Formulas for estimating averted direct medical costs of HIV

HIV costs averted by reducing HIV transmission through treatment of chlamydia, gonorrhea, and syphilis
Chlamydia	[(Ĉ_w + Ĉ_m)(0.0011)(0.25)(0.75)($198,471)] + [(Ĉ_msm)(0.0011)(0.25)(0.50)(0.25)($198,471)]
Gonorrhea	[(Ĝ_w + Ĝ_m)(0.0007)(0.25)(0.75)($198,471)] + [(Ĝ_msm)(0.0007)(0.25)(0.50)(0.25)($198,471)]
Syphilis	[(Ŝ_w + Ŝ_m)(0.02386)(0.25)(0.75)($198,471)] + [(Ŝ_msm)(0.02386)(0.25)(0.50)(0.25)($198,471)]
HIV costs averted by HIV counseling and testing
	[(X₁₂ + Y₁₂)(0.00045)(0.75)(0.875)($198,471)] + [(Z₁₂)(0.00045)(0.50)(0.25)(0.875)($198,471)]

The C_i, G_i, S_i, Ĉ_i, Ĝ_i, and Ŝ_i terms are defined in Table 3. The X_i, Y_i, and Z_i terms are defined in Table 2. Syphilis cases include primary and secondary (P&S) syphilis only.

ISSN: 1478-7547